Evidence map›Paper›PMID 34711189›Full record

ArticleBMC infectious diseases2021

Using MALDI-TOF spectra in epidemiological surveillance for the detection of bacterial subgroups with a possible epidemic potential.

Audrey Giraud-Gatineau, Gaetan Texier, Pierre-Edouard Fournier, Didier Raoult, Hervé Chaudet

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03626987 (Identification of Protein Markers of Epidemiological and Clinical Interest by MALDI-TOF), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03626987 unknown statusnot on this map

Identification of Protein Markers of Epidemiological and Clinical Interest by MALDI-TOF

TypeobservationalSponsorAssistance Publique Hopitaux De MarseilleRan2018 to 2022Enrolled600,000ConditionsInfectious RiskArmsmass spectrometry (MALDI-TOF)
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Exploring the Utility of MALDI-TOF Mass Spectrometry and Antimicrobial Resistance in Hospital Outbreak Detection.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Genome assembly ofFrontiers in microbiology · 2025
    Article
  9. Review
  10. Article
  11. Antibiotic resistance surveillance ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Audrey Giraud-GatineauInstitut Hospitalo-Universitaire Méditerranée-Infection, 19-21 Boulevard Jean Moulin, 13005, Marseille, France.
Gaetan TexierAix Marseille Univ., IRD, AP-HM, SSA, VITROME, IHU Méditerranée Infection, Marseille, France.
Pierre-Edouard FournierInstitut Hospitalo-Universitaire Méditerranée-Infection, 19-21 Boulevard Jean Moulin, 13005, Marseille, France.
Didier RaoultInstitut Hospitalo-Universitaire Méditerranée-Infection, 19-21 Boulevard Jean Moulin, 13005, Marseille, France.
Hervé ChaudetInstitut Hospitalo-Universitaire Méditerranée-Infection, 19-21 Boulevard Jean Moulin, 13005, Marseille, France. herve.chaudet@gmail.com.
Aix-Marseille Université · FRAssistance Publique Hôpitaux de Marseille · FRInstitut de Recherche pour le Développement · FRMéditerranée Infection Foundation · FR

Funding

French Ministry of Health for the Hospital Clinical Research Program PHRC 2016_098
6 · The paper itself

Abstract

backgroundFor the purpose of epidemiological surveillance, the Hospital University Institute Méditerranée infection has implemented since 2013 a system named MIDaS, based on the systematic collection of routine activity materials, including MALDI-TOF spectra, and results. The objective of this paper is to present the pipeline we use for processing MALDI-TOF spectra during epidemiological surveillance in order to disclose proteinic cues that may suggest the existence of epidemic processes in complement of incidence surveillance. It is illustrated by the analysis of an alarm observed for Streptococcus pneumoniae.

methodsThe MALDI-TOF spectra analysis process looks for the existence of clusters of spectra characterized by a double time and proteinic close proximity. This process relies on several specific methods aiming at contrasting and clustering the spectra, presenting graphically the results for an easy epidemiological interpretation, and for determining the discriminating spectra peaks with their possible identification using reference databases.

resultsThe use of this pipeline in the case of an alarm issued for Streptococcus pneumoniae has made it possible to reveal a cluster of spectra with close proteinic and temporal distances, characterized by the presence of three discriminant peaks (5228.8, 5917.8, and 8974.3 m/z) and the absence of peak 4996.9 m/z. A further investigation on UniProt KB showed that peak 5228.8 is possibly an OxaA protein and that the absent peak may be a transposase.

conclusionThis example shows this pipeline may support a quasi-real time identification and characterization of clusters that provide essential information on a potentially epidemic situation. It brings valuable information for epidemiological sensemaking and for deciding on the continuation of the epidemiological investigation, in particular the involving of additional costly resources to confirm or invalidate the alarm. CLINICAL TRIALS REGISTRATION: NCT03626987.

Indexed as

BacteriaEpidemicsCluster AnalysisHumansSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStreptococcus pneumoniaeCluster analysisEpidemicEpidemiological surveillanceMALDI-TOF

Identifiers

PMID34711189
PMCPMC8554970
OpenAlexW3168856237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.